A review of the health economic and resource utilization literature for the use of tigecycline treatment of complicated intra-abdominal infections

Main Article Content

Bruce Wang YiXi Chen Wesley Furnback Peng Dong Ahmed Shelbaya



Complicated intra-abdominal infections (cIAIs) infect deep soft tissues requiring surgical interventions and often result in decreased quality of life due to hospitalization.  In addition to tigecycline, treatment of cIAI includes other drugs such as ceftriaxone, ciprofloxacin, imipenem, and levofloxacin.  In this study, we conducted a literature review using publically-available databases focusing on the health economic and resource utilization estimates of tigecycline and the other agents as first-line treatment of cIAIs. 


The databases used in this systematic review included PubMed and 42 unique HTA organizations.  Search terms included “tigecycline” in combination with “Health Economics,” “Resource Utilization,” “Cost-Effectiveness,” and “Length of Stay.” The search criteria excluded articles with the following characteristics: without abstracts, published over 10 years ago, or not in English.  Articles were then determined for eligibility using four additional inclusion criteria: 1) Indication, 2) Bacteria Type, 3) Qualitative Assessment, 4) Technicality.  Studies were analyzed independently and not pooled because this was not a meta-analysis. 


After applying our filters to the search criteria, we identified 9 unique papers on the health economics and resource utilization of using tigecycline as first-line treatment of cIAIs.  Though the health economic search resulted in only a few number papers on the cost-effectiveness of tigecycline, the messaging was consistent: tigecycline showed competitive clinical effectiveness and economic resource utilization versus several different comparators despite higher acquisition expenses.  Several studies established that in terms of length of stay (LoS), total costs of hospitalization and other resource utilization parameters tigecycline was not inferior and thus the results do not favor one treatment over another.


The health economics literature estimates tigecycline to have comparable total cost per patient with respect to comparators.  The broad spectrum activity of the drug avoids inappropriate treatments which are associated with increased resource utilization and result in higher costs.  In view of the alarming spread in antibiotic resistance, the addition of another treatment option offers a valuable tool to counteract a mono-culture of therapies applied against cIAIs.

Article Details

How to Cite
WANG, Bruce et al. A review of the health economic and resource utilization literature for the use of tigecycline treatment of complicated intra-abdominal infections. Medical Research Archives, [S.l.], n. 3, july 2015. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/283>. Date accessed: 03 oct. 2022.
cIAIs; HEOR; Tigecycline
Review Articles


[1] Reardon, S. (2014) WHO warns against ‘post-antibiotic’ era. Nature. doi:10.1038

[2] US Department of Health and Human Services, Centres for Disease Control and Prevention. (2013) Antibiotic Resistance Threat in the United States, Centres for Diseases Control and Prevention, National Centres for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP).

[3] U.S. Department of Health and Human Services. (2011) Centers for Disease Control and Prevention. Antimicrobial Resistance Posing Growing Health Threat. N.p., 7 Apr. Web. 07 Nov. 2014.

[4] Hu F, Chen S, Xu X, Guo Y, Liu Y, et al. (2012) Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol. 2012 Jan;61(Pt 1):132-6. doi:10.1099/jmm.0.036483-0. Epub 2011 Sep 8.

[5] World Health Organization. (2014) Antimicrobila resistance: global report on surveillance 2014. WHO press, ISBN: 978 92 4 156474 8.

[6] Projan SJ. (2000) Preclinical Pharmacology of GAR-936, A Novel Glycylcycline Anitibacterial Agent. Pharmacother 2000; 20(9): 219S-223S.

[7] Projan SJ. (2010) Francis Tally and the Discovery and Development of Tigecycline: A Personal Reminiscence. Clin Infect Dis. 50: S24-5.

[8] Loh E, Ellis-Grosse E, Petersen PJ, Sum PE, Projan S. (2007) Tigecycline: a case study. Expert Opin. Drug Discov. 2(3): 403-418.

[9] Doan TL, Fung HB, Mehta D, Riska PF. (2006) Tigecycline: A Glycylcycline Antimicrobial Agent. Clin Therap. 28(8): 1078-1106. doi: 10.1015/j.clinthera.2005.08.011

[10] Eandi M. (2009) Hospital management of complicated intra-abdominal infections: pharmacoeconomic evaluation. J Chemother. Jul;21 Suppl 1:44-55.

[11] Di Carlo P, Gulotta G, Casuccio A, Pantuso G, Raineri M, et al. (2013) KPC – 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol. Jul 3;13(1):13. doi: 10.1186/1471-2253-13-13.

[12] Mallick R, Sun S, Schell SR. (2007) Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt). Apr;8(2):159-72.

[13] Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, et al. (2008) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother. Oct;20 Suppl 1:12-9.

[14] Wilke MH. (2010) Multiresistant bacteria and current therapy - the economical side of the story. Eur J Med Res. Nov 30;15(12):571-6. Review.

[15] Nicolau DP. (2009) Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother. May;10(7):1213-22. doi: 10.1517/14656560902900853 . Review. Erratum in: Expert Opin Pharmacother. 2009 Jun;10(9):1527.

[16] Blot S, De Waele JJ, Vogelaers D. (2012) Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012 Apr 16;72(6):e17-32. doi: 10.2165/11599800-000000000-00000.

[17] Reygaert WC. (2010) Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther Clin Risk Manag. Sep 7;6:419-30.

[18] Dunn CJ. (2006) Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections. Core Evid. 1(3):181-94.

[19] Tygacil (tigecycline) fact sheet, Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc.